骨科植入物

Search documents
三友医疗: 公司2025年半年度募集资金存放与使用情况的专项报告
Zheng Quan Zhi Xing· 2025-08-25 17:19
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 根据中国证券监督管理委员会《上市公司募集资金监管规则》、《上海证券 交易所科创板上市公司自律监管指引第 1 号——规范运作》以及《上海证券交易 所上市公司自律监管指南第 1 号——公告格式》的相关规定,本公司就 2025 年 半年度募集资金存放与使用情况作如下专项报告: 一、募集资金基本情况 上海三友医疗器械股份有限公司 (一)实际募集资金金额、资金到位时间 核准,并经上海证券交易所同意,本公司向社会公众公开发行普通股(A 股)股 票 5,133.35 万股,每股面值 1 元,每股发行价人民币 20.96 元。截至 2020 年 4 月 1 日,本公司共募集资金 1,075,950,160.00 元,扣除发行费用 97,892,778.72 元, 募集资金净额 978,057,381.28 元。上述发行募集的资金已全部到位,并经立信会 计师事务所(特殊普通合伙)以"信会师报字[2020]第 ZA10508 号"验资报告验 证确认。 证券代码:688085 证券简称:三友医疗 ...
西安赛隆新三板上市问询回复,揭示其面临的产业化机遇与挑战
Sou Hu Cai Jing· 2025-08-17 03:33
Core Viewpoint - Xian Sailong Co., Ltd. is strategically positioned in the metal additive manufacturing sector, focusing on a full-chain layout of "powder production equipment + electron beam 3D printing equipment + printing services" [3] Company Overview - In 2024, the company achieved a revenue of 85.0172 million yuan, representing a year-on-year growth of 23.04%, with a significant increase of 274.67% in revenue from 3D printing products and services [3] - The company has established an annual production line for 100,000 orthopedic implants, with plans to expand to 300,000 units per year [3] - Current production capacity includes 75 units of 3D printing equipment and 23 units of powder production equipment, but utilization rates are low at 44% for 3D printing equipment, 26% for powder production equipment, and 38.96% for 3D printing products [3] Financial Performance - In 2024, the company reported a net loss of 24.3463 million yuan, which is an increase compared to the previous year's loss, attributed to rising depreciation from new facilities, increased financial expenses due to loan interest, and higher management costs [4] - The cash flow from operating activities remains negative but has shown significant improvement compared to last year [4] - The estimated breakeven sales scale is approximately 181 million yuan, with expectations to reach breakeven by Q3 2027, contingent on increasing utilization rates to 50% for 3D printing equipment, 30% for powder production equipment, and 89% for 3D printing products [4] Market Dynamics - The global additive manufacturing market reached a size of 21.9 billion USD in 2024, with a year-on-year growth of 9.1%, projected to reach 114.5 billion USD by 2034, reflecting a compound annual growth rate (CAGR) of 18% [5] - The metal additive manufacturing segment is particularly robust, with a market size of 4.7 billion USD in 2024, expected to exceed 60 billion USD in ten years, showing a CAGR of 29% [5] - The Chinese market is also experiencing rapid growth, with an expected industry scale of 41.5 billion yuan in 2024, projected to surpass 120 billion yuan by 2029 [5] Competitive Landscape - The electron beam powder bed fusion (EB-PBF/EBM) technology is entering a critical phase of industrialization, with advantages over laser powder bed fusion (LPBF) in processing high-melting-point materials [5][6] - Key competitors include Qingyan Zhishu, which has made breakthroughs in multi-gun arrays and large-format capabilities, and LPBF companies like Huazhu Gaoke and Bolite, which maintain advantages in process maturity and customer base [6] - The competition between electron beam and laser technologies is characterized by coexistence, with each suited for different applications [6] Opportunities for the Company - The company has the potential to narrow the gap with competitors by iterating technology and leveraging its full industry chain to reduce costs and bind customers [7] - If the company can demonstrate the long-term cost and quality advantages of electron beam technology through benchmark projects between 2025 and 2027, it may establish a stable market position [7] - However, challenges include potential delays in technology maturity, customer preference for LPBF, and cash flow pressures if capacity utilization does not improve as planned [7]
身价300亿,威海首富收获第四个IPO
投中网· 2025-05-28 06:35
以下文章来源于东四十条资本 ,作者蒲凡 东四十条资本 . 聚焦股权投资行业人物、事件、数据、研究、政策解读,提供专业视角和深度洞见 | 创投圈有趣的灵魂 将投中网设为"星标⭐",第一时间收获最新推送 一轮融资就搞定的IPO。 作者丨 蒲凡 来源丨 东四十条资本 威海"首富"陈学利拿下了他的第四家上市公司。 近日,山东威高血液净化制品股份有限公司(以下简称"威高血净")正式在上海证券交易所主板挂牌,IPO发行价格为每股 26.50元人民币,上市首日开盘价上涨88.64%报49.99元,市值一度突破200亿元,远高于上市递表时的目标估值。 虽然上 市后持续股价持续下挫,但市值仍然接近150亿元。 3年前,威高血净曾经申报过港股IPO,后于2023年底改道A股,当时IPO目标估值为135.1亿元,现在无疑算是超额完成了 任务。根据招股书显示,威高血净已经成为了血液透析器材领域内当之无愧的龙头老大,无论统计整个国内血液透析器领 域,还是细分到血液透析管路领域,市场份额均超过32%。 威高血净"系出名门"。在本次申报IPO之前,威高血净的母公司威高集团旗下已经拥有了两家上市公司和一家准上市公司, 分别是从一次性输液器起 ...
三友医疗去年扣非亏损 已完成关联收购2020上市募10.8亿
Zhong Guo Jing Ji Wang· 2025-05-17 07:23
2025年第一季度,公司实现营业收入1.16亿元,同比增长34.72%;归属于上市公司股东的净利润1282.34万元,同比扭亏;归属于上市 公司股东的扣非净利润1143.18万元,同比扭亏;经营活动产生的现金流量净额为-1643.88万元,上年同期为-4959.37万元。 中国经济网北京5月17日讯三友医疗(688085.SH)近日披露2024年年度报告。2024年,公司实现营业收入4.54亿元,同比下降1.48%;归属 于上市公司股东的净利润1146.86万元,同比下降88.00%;归属于上市公司股东的扣非净利润为-378.10万元,上年同期为5928.46万元; 经营活动产生的现金流量净额为1096.47万元,同比下降95.90%。 | 项目 | 本报告期 | 上年同期 | 本报告期比上 年同期增减变 | | --- | --- | --- | --- | | | | | 动幅度(%) | | 营业收入 | 116, 434, 264. 40 | 86, 429, 306. 35 | 34. 72 | | 归属于上市公司股东的净利润 | 12,823,438.55 | -2, 095, 834. 44 | ...